OBJECTIVE: To report the treatment efficacy and toxicity profile of intensity-modulated radiation therapy in Chinese patients with clinically localised prostate cancer.
DESIGN: Historical cohort study.
SETTING: Oncology unit in a university teaching hospital in Hong Kong.
PATIENTS: Patients with clinically localised prostate cancer undergoing intensity-modulated radiation therapy in our institution between May 2001 and November 2009 were reviewed.
MAIN OUTCOME MEASURES: The 5-year biochemical failure-free survival, 5-year overall survival, as well as acute/late gastro-intestinal toxicities and genito-urinary toxicities.
RESULTS: A total of 182 patients were treated with prostate intensity-modulated radiation therapy with or without whole-pelvic radiotherapy. The median follow-up was 44 months. The median patient age was 72 years. Overall survival of the cohort was 92% after 5 years. The favourable, intermediate, and unfavourable risk category distributions of the National Comprehensive Cancer Network were 21 (12%), 42 (23%), and 119 (65%), respectively. The 5-year actuarial biochemical failure-free survival rates for patients in these categories were 95%, 82%, and 80%, respectively. Multivariate analysis identified early tumour stage, low pre-treatment prostate-specific antigen levels, and the use of adjuvant androgen deprivation as independent prognostic factors for better biochemical failure-free survival. Grade 2 and 3 late gastro-intestinal/genito-urinary toxicities occurred in 8%/3% and 4%/3% of the patients, respectively.
CONCLUSION: Intensity-modulated radiation therapy for prostate cancer is feasible and safe in the Chinese population. These data are consistent with the results of other series in Caucasian populations.
Written by:
Poon DM, Chan SL, Leung CM, Lee KM, Kam MK, Yu BK, Chan AT. Are you the author?
Department of Clinical Oncology, State Key Laboratory in Oncology in South China; Sir YK Pao Centre for Cancer, Hong Kong Cancer Institute; and Prince of Wales Hospital, The Chinese University of Hong Kong, Shatin, Hong Kong.
Reference: Hong Kong Med J. 2013 Jun 20. Epub ahead of print.
doi: 10.12809/hkmj133815
PubMed Abstract
PMID: 23784530
UroToday.com Prostate Cancer Section
